Chen M, Li S, Xie W, Wang B, Chen D
Department of Biochemistry, Rush University Medical Center, 1735 West Harrison Street, Cohn Research Building, Suite 508, Chicago, IL 60612,
Eur Cell Mater. 2014 Oct 23;28:236-45. doi: 10.22203/ecm.v028a16.
In 2007 and 2008, we published two articles reporting a tamoxifen (TM)-inducible, chondrocyte-specific gene-targeting mouse model in which the expression of CreER(T2) is driven by the type II collagen promoter (Col2CreER(T2)). The fusion protein is specifically expressed and translocated into the nucleus upon TM administration, which in turn triggers gene recombination. Since then, this animal model has become a powerful tool to study the molecular mechanism of skeletal development and degenerative cartilage diseases, including knee joint osteoarthritis (OA), temporomandibular joint (TMJ) OA, and intervertebral disc (IVD) degeneration. In this review article, we summarise the application of Col2CreER(T2) mice and discuss the potential usage of this animal model in a broad spectrum of cartilage development and molecular pathology studies.
2007年和2008年,我们发表了两篇文章,报道了一种他莫昔芬(TM)诱导的、软骨细胞特异性基因靶向小鼠模型,其中CreER(T2)的表达由II型胶原启动子(Col2CreER(T2))驱动。给予TM后,融合蛋白特异性表达并转移至细胞核,进而触发基因重组。自那时起,该动物模型已成为研究骨骼发育和退行性软骨疾病分子机制的有力工具,这些疾病包括膝关节骨关节炎(OA)、颞下颌关节(TMJ)OA和椎间盘(IVD)退变。在这篇综述文章中,我们总结了Col2CreER(T2)小鼠的应用,并讨论了该动物模型在广泛的软骨发育和分子病理学研究中的潜在用途。